JP2017505284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505284A5 JP2017505284A5 JP2016531028A JP2016531028A JP2017505284A5 JP 2017505284 A5 JP2017505284 A5 JP 2017505284A5 JP 2016531028 A JP2016531028 A JP 2016531028A JP 2016531028 A JP2016531028 A JP 2016531028A JP 2017505284 A5 JP2017505284 A5 JP 2017505284A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- amino
- acetyl
- hpyy
- carboxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 119
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 73
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 67
- -1 PYY compound Chemical class 0.000 claims 40
- 101100289894 Caenorhabditis elegans lys-7 gene Proteins 0.000 claims 30
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 23
- 208000008589 Obesity Diseases 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 6
- 125000006308 propyl amino group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010006550 Bulimia nervosa Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 229940005529 antipsychotics Drugs 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000003915 cell function Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 230000030135 gastric motility Effects 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000036186 satiety Effects 0.000 claims 2
- 235000019627 satiety Nutrition 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 1
- 108010019598 Liraglutide Proteins 0.000 claims 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960002701 liraglutide Drugs 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229950011186 semaglutide Drugs 0.000 claims 1
- 108010060325 semaglutide Proteins 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- 0 CS(CCCCCCCCCCCCCCCC(N[C@@](CCC(NCCOCCOCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@](C(*)=O)N*)=O)=O)=O)=O)C(O)=O)=O)(O)(O)O Chemical compound CS(CCCCCCCCCCCCCCCC(N[C@@](CCC(NCCOCCOCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@](C(*)=O)N*)=O)=O)=O)=O)C(O)=O)=O)(O)(O)O 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13193082.8 | 2013-11-15 | ||
| EP13193082 | 2013-11-15 | ||
| US201361906020P | 2013-11-19 | 2013-11-19 | |
| US61/906,020 | 2013-11-19 | ||
| EP14176725 | 2014-07-11 | ||
| EP14176725.1 | 2014-07-11 | ||
| PCT/EP2014/074476 WO2015071355A1 (en) | 2013-11-15 | 2014-11-13 | Selective pyy compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019117619A Division JP2019189632A (ja) | 2013-11-15 | 2019-06-25 | 選択的なｐｙｙ化合物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505284A JP2017505284A (ja) | 2017-02-16 |
| JP2017505284A5 true JP2017505284A5 (enExample) | 2017-12-21 |
| JP6602760B2 JP6602760B2 (ja) | 2019-11-06 |
Family
ID=53056816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531028A Active JP6602760B2 (ja) | 2013-11-15 | 2014-11-13 | 選択的なｐｙｙ化合物及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10246497B2 (enExample) |
| EP (1) | EP3068421B1 (enExample) |
| JP (1) | JP6602760B2 (enExample) |
| KR (1) | KR20160075819A (enExample) |
| CN (1) | CN105722526B (enExample) |
| AU (1) | AU2014350197B2 (enExample) |
| BR (1) | BR112016010383A2 (enExample) |
| CA (1) | CA2929672A1 (enExample) |
| IL (1) | IL245045B (enExample) |
| MX (1) | MX369818B (enExample) |
| PL (1) | PL3068421T3 (enExample) |
| RS (1) | RS59026B1 (enExample) |
| SI (1) | SI3068421T1 (enExample) |
| TW (1) | TWI661835B (enExample) |
| WO (1) | WO2015071355A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
| EP4324475A1 (en) | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| SG11201508469YA (en) * | 2013-05-02 | 2015-11-27 | Glaxosmithkline Ip Dev Ltd | Therapeutic peptides |
| KR20210086717A (ko) | 2013-05-02 | 2021-07-08 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| JP6629198B2 (ja) * | 2013-11-15 | 2020-01-15 | ノヴォ ノルディスク アー／エス | ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６） |
| US10246497B2 (en) | 2013-11-15 | 2019-04-02 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| CA2988500A1 (en) * | 2015-06-12 | 2016-12-15 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| US12569543B2 (en) * | 2016-04-28 | 2026-03-10 | Novo Nordisk A/S | Semaglutide in cardiovascular conditions |
| MA46780A (fr) | 2016-11-07 | 2019-09-11 | Novo Nordisk As | Esters à dchbs actif de composés peg et leur utilisation |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| JP2020527159A (ja) | 2017-07-19 | 2020-09-03 | ノヴォ ノルディスク アー／エス | Ｅｇｆ（ａ）類似体、その製造、製剤および使用 |
| HUE066356T2 (hu) | 2017-08-24 | 2024-07-28 | Novo Nordisk As | GLP-1 készítmények és alkalmazásaik |
| EP3717508A1 (en) | 2017-12-01 | 2020-10-07 | The University of Copenhagen | Peptide hormone with one or more o-glycans |
| KR20200131812A (ko) * | 2018-01-09 | 2020-11-24 | 길라 테라퓨틱스, 인코포레이티드 | 대사 질병을 치료하기 위한 조성물 및 방법 |
| WO2019149880A1 (en) | 2018-02-02 | 2019-08-08 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| GB2573145A (en) | 2018-04-26 | 2019-10-30 | Univ Ulster | Peptides for metabolic disease |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| TW202535916A (zh) * | 2018-11-01 | 2025-09-16 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| CN114206375A (zh) * | 2019-08-07 | 2022-03-18 | 诺和诺德股份有限公司 | 包含pyy化合物和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物 |
| MX2022005661A (es) * | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
| UA130066C2 (uk) | 2020-08-07 | 2025-10-29 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Розчинні агоністи рецепторів npy2 |
| KR20230106616A (ko) * | 2020-11-09 | 2023-07-13 | 엠바크 바이오테크 에이피에스 | 타키키닌 수용체 매개 장애의 치료에 있어서의 화합물 및 이의 용도 |
| WO2024038067A1 (en) | 2022-08-18 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
| WO2025128626A1 (en) * | 2023-12-12 | 2025-06-19 | Carmot Therapeutics, Inc. | Hybrid peptide compounds having a modified lysine residue |
| WO2025128624A2 (en) * | 2023-12-12 | 2025-06-19 | Carmot Therapeutics, Inc. | Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0692971A4 (en) | 1993-03-29 | 1997-11-12 | Univ Cincinnati | PEPTID YY ANALOGS AND USES THEREFOR |
| US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
| WO1998020885A1 (en) | 1996-11-13 | 1998-05-22 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
| EP0908515A3 (en) | 1997-09-16 | 2000-04-26 | Smithkline Beecham Plc | Pancreatic polypeptide |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| MY133223A (en) | 1998-06-08 | 2007-10-31 | Schering Corp | Neuropeptide y5 receptor antagonists |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| AU2002230843B8 (en) | 2000-12-14 | 2007-05-17 | Amylin Pharmaceuticals, Llc | Peptide YY and peptide YY agonists for treatment of metabolic disorders |
| US6589938B2 (en) | 2001-06-29 | 2003-07-08 | National University Of Singapore | Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| PL205971B1 (pl) | 2001-09-24 | 2010-06-30 | Imp Innovations Ltd | Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| EP1583549A4 (en) | 2003-01-17 | 2006-10-04 | Sod Conseils Rech Applic | YY PEPTIDE ANALOGS |
| US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
| TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
| CN101380476A (zh) | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| CA2550050A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
| JP5638177B2 (ja) | 2004-02-11 | 2014-12-10 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド |
| US20060094652A1 (en) | 2004-02-11 | 2006-05-04 | Levy Odile E | Hybrid polypeptides with selectable properties |
| EA011860B1 (ru) | 2004-03-17 | 2009-06-30 | 7ТиЭм ФАРМА А/С | Селективные агонисты рецептора y2 для терапевтического воздействия |
| AU2005224027B2 (en) | 2004-03-17 | 2011-05-26 | 7Tm Pharma A/S | Y2/Y4 selective receptor agonists for therapeutic interventions |
| CN100425282C (zh) | 2004-03-17 | 2008-10-15 | 7Tm制药联合股份有限公司 | 用于治疗性干预的y2/y4选择性受体激动剂 |
| PL2060266T3 (pl) | 2004-03-17 | 2012-01-31 | 7Tm Pharma As | Selektywni agoniści PP2-36 receptora Y4 do interwencji terapeutycznych |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| ES2564167T3 (es) | 2004-07-08 | 2016-03-18 | Novo Nordisk A/S | Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol |
| US7994119B2 (en) | 2004-07-19 | 2011-08-09 | University Of Cincinnati | Compounds for control of appetite |
| WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
| US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| KR20080033392A (ko) | 2005-07-11 | 2008-04-16 | 나스텍 파마수티컬 컴퍼니 인코포레이티드 | 펩타이드 ｙｙ의 향상된 점막 전달을 위한 제형들 |
| CA2616583A1 (en) | 2005-07-18 | 2007-01-25 | Novo-Nordisk A/S | Peptides for use in the treatment of obesity |
| EA200800875A1 (ru) | 2005-09-21 | 2008-08-29 | 7ТиЭм ФАРМА А/С | Рецепторные агонисты, селективные к y2 рецептору, для терапевтического воздействия |
| EA200800874A1 (ru) | 2005-09-21 | 2008-08-29 | 7ТиЭм ФАРМА А/С | Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия |
| WO2007065808A2 (en) | 2005-12-07 | 2007-06-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor-agonists |
| WO2007068718A1 (en) | 2005-12-14 | 2007-06-21 | Novo Nordisk A/S | Polypeptide protracting tags |
| US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
| EP2004238A2 (en) | 2006-03-21 | 2008-12-24 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| US20090099074A1 (en) | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
| WO2008087190A2 (en) | 2007-01-18 | 2008-07-24 | Novo Nordisk A/S | Use of peptides in combination with surgical intervention for the treatment of obesity |
| WO2008087186A2 (en) | 2007-01-18 | 2008-07-24 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| GB0708226D0 (en) | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
| CN101970475A (zh) | 2007-07-09 | 2011-02-09 | 帝国改革有限公司 | 人类胰多肽(hpp)类似物及其对摄食行为的作用 |
| WO2009030771A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| AU2008297885A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of GLP-1 as a therapeutic agent |
| EP2195034A2 (en) | 2007-09-27 | 2010-06-16 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
| WO2009138511A1 (en) | 2008-05-16 | 2009-11-19 | Novo Nordisk A/S | Long-acting y2 and/or y4 receptor agonists |
| US8299023B2 (en) | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
| GB0817067D0 (en) | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
| CN102202681A (zh) | 2008-11-05 | 2011-09-28 | 霍夫曼-拉罗奇有限公司 | 神经肽-2受体(y-2r)激动剂及其用途 |
| CA2752608A1 (en) | 2009-02-20 | 2010-08-26 | Ipsen Pharma S.A.S. | Cytotoxic conjugates having neuropeptide y receptor binding compound |
| EP2477643A1 (en) | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| WO2011045232A2 (en) | 2009-10-13 | 2011-04-21 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor (y-2r) agonists |
| WO2011058165A1 (en) | 2009-11-13 | 2011-05-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| EP2560675A1 (en) | 2010-04-20 | 2013-02-27 | Novo Nordisk A/S | Long-acting gastrin derivatives |
| WO2011138421A1 (en) * | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
| GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| EP2855517A1 (en) | 2012-05-29 | 2015-04-08 | Novo Nordisk A/S | Pancreatic polypeptide compounds and use |
| SG11201508469YA (en) * | 2013-05-02 | 2015-11-27 | Glaxosmithkline Ip Dev Ltd | Therapeutic peptides |
| JP6629198B2 (ja) | 2013-11-15 | 2020-01-15 | ノヴォ ノルディスク アー／エス | ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６） |
| US10246497B2 (en) * | 2013-11-15 | 2019-04-02 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| CA2988500A1 (en) * | 2015-06-12 | 2016-12-15 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
-
2014
- 2014-11-13 US US15/036,201 patent/US10246497B2/en active Active
- 2014-11-13 PL PL14798834T patent/PL3068421T3/pl unknown
- 2014-11-13 MX MX2016006053A patent/MX369818B/es active IP Right Grant
- 2014-11-13 RS RS20190792A patent/RS59026B1/sr unknown
- 2014-11-13 CA CA2929672A patent/CA2929672A1/en not_active Withdrawn
- 2014-11-13 SI SI201431251T patent/SI3068421T1/sl unknown
- 2014-11-13 US US14/540,474 patent/US9085637B2/en active Active
- 2014-11-13 EP EP14798834.9A patent/EP3068421B1/en active Active
- 2014-11-13 BR BR112016010383A patent/BR112016010383A2/pt not_active Application Discontinuation
- 2014-11-13 TW TW103139321A patent/TWI661835B/zh not_active IP Right Cessation
- 2014-11-13 AU AU2014350197A patent/AU2014350197B2/en not_active Ceased
- 2014-11-13 KR KR1020167015805A patent/KR20160075819A/ko not_active Withdrawn
- 2014-11-13 JP JP2016531028A patent/JP6602760B2/ja active Active
- 2014-11-13 CN CN201480062213.5A patent/CN105722526B/zh active Active
- 2014-11-13 WO PCT/EP2014/074476 patent/WO2015071355A1/en not_active Ceased
-
2016
- 2016-04-11 IL IL245045A patent/IL245045B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522843A5 (enExample) | ||
| RU2017145348A (ru) | Селективные соединения пептида yy и их применения | |
| JP2017500289A5 (enExample) | ||
| JP6379300B2 (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| Cho et al. | K-cells and glucose-dependent insulinotropic polypeptide in health and disease | |
| RU2523552C2 (ru) | Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета | |
| FI3827015T3 (fi) | Gip/glp1-koagonistiyhdisteitä | |
| JP2017519739A5 (enExample) | ||
| JP2017537612A5 (enExample) | ||
| UA126960C2 (uk) | Похідна глюкагону | |
| BRPI0606992A2 (pt) | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis | |
| JP2014129355A5 (enExample) | ||
| RU2016135543A (ru) | Новые производные инсулина и их применение в медицине | |
| WO2014206563A2 (en) | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases | |
| JP2011526482A5 (enExample) | ||
| JP2014503593A5 (enExample) | ||
| Liu et al. | Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): current knowledge of mechanisms | |
| JP2015517458A5 (enExample) | ||
| ES3057685T3 (en) | Treatment of liver, biliary tract and pancreatic disorders with defensins | |
| CN113456820B (zh) | 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途 | |
| JP2013511287A5 (enExample) | ||
| JP2014500244A5 (enExample) | ||
| RU2012126101A (ru) | Полипептидный конъюгат | |
| JP2020500930A5 (enExample) | ||
| JP2013532970A5 (enExample) |